drugset / Trial / NCT01642602

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents

NCT01642602

Phase 2 Completed 104 enrolled Takeda
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to assess the safety and effectiveness of once daily oral administration of dexlansoprazole delayed-release capsules in adolescent participants with symptomatic non-erosive gastroesophageal reflux disease (GERD).

Timeline

Start
2012-07
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexlansoprazole Other / unclassified 30 mg Oral